| Literature DB >> 29768206 |
Janet H Zheng1, Christy R Grace2, Cristina D Guibao1, Dan E McNamara1, Fabien Llambi3, Yue-Ming Wang4, Taosheng Chen4, Tudor Moldoveanu5.
Abstract
The effector B cell lymphoma-2 (BCL-2) protein BCL-2 ovarian killer (BOK) induces mitochondrial outer membrane permeabilization (MOMP) to initiate apoptosis upon inhibition of the proteasome. How BOK mediates MOMP is mechanistically unknown. The NMR structure of the BCL-2 core of human BOK reveals a conserved architecture with an atypical hydrophobic groove that undergoes conformational exchange. Remarkably, the BCL-2 core of BOK spontaneously associates with purified mitochondria to release cytochrome c in MOMP assays. Alanine substitution of a unique glycine in helix α1 stabilizes BOK, as shown by thermal shift and urea denaturation analyses, and significantly inhibits MOMP, liposome permeabilization, and cell death. Activated BID does not activate WT BOK or the stabilized alanine mutant to promote cell death. We propose that BOK-mediated membrane permeabilization is governed in part by its unique metastability of the hydrophobic groove and helix α1 and not through activation by BH3 ligands.Entities:
Keywords: BH3-only proteins; apoptosis; binding-induced activation; cytochrome c release; effector BCL-2 proteins; liposome permeabilization; mitochondrial outer membrane permeabilization
Mesh:
Substances:
Year: 2018 PMID: 29768206 PMCID: PMC6500462 DOI: 10.1016/j.celrep.2018.04.060
Source DB: PubMed Journal: Cell Rep Impact factor: 9.423
Figure 1.BOK-Mediated Membrane Permeabilization Correlates with Its Metastability
(A) Human BOK constructs used in this study. The BCL-2 homology regions (BH1–BH4), TM, residue numbers, and tags are indicated for BOK constructs.
(B) LUVP measured as fluorescent dye release by FL-BOK-DTM-CH was normalized relative to permeabilization by 2.5% 3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonate hydrate (CHAPS). Normalized data were analyzed by Simpson’s rule AUC at 32 min. Data represent the average and SD for one of three experiments performed in triplicate.
(C) Combined average and SE AUC at 32 min for the BOK constructs. Related to Figure S1C.
(D) Combined average and SE of BOK concentration required to achieve half-maximal AUC at 32 min for the BOK constructs (related to Figure S1D).
(E) MOMP assays of purified bak− mitochondria were performed for 1 hr at 37°C for monitoring cyt c release and protein loading.
(F) Thermal denaturation measured by TSA at 0.25 mg/mL protein was performed using the manufacturer’s buffer conditions. Data represent average melting temperature (Tm) and SD of replicate performed in quadruplicate.
See also Figure S1.
Figure 2.NMR Structure of Human BOK Reveals a Typical BCL-2 Core
(A) Overlay of 1H-15N TROSY spectra of the BCL-2 core of BOK, PR3CA ΔN20-BOK-ΔC35, and the G35A mutant, with some assignments illustrating chemical shift perturbation between the two.
(B) Cartoon representation of the NMR structure of the BCL-2 core of BOK. BH1–BH4 regions are colored as in Figure 1A.
(C) Protein dynamics analyses including backbone 1H-15N transverse (R2) and longitudinal (R1) relaxation and hetNOE analysis of WT and G35A PR3CA revealed two flexible regions, the α1–α2 and the α2–α4 connecting regions, both having hetNOE values lower than the domain average. The R2, R1, and τc analyses indicated that the α1–α2 and α2–α4 connecting regions had faster and slower motions than the domain average, respectively, suggesting nanosecond to picosecond dynamics for the former and chemical (conformational) exchange microsecond to millisecond dynamics for the latter. The unique properties of the α2–α4 connecting region, which also harbors the short helix α3, likely contribute to the overall meta-stability of BOK. The stabilizing G35A mutant in helix a1 reduces but does not abolish the dynamics in the α2–α4 connecting region, suggesting a global effect on BOK metastability.
See also Figure S2.
Figure 3.Structural Comparison Reveals Possible Gating of BH3 Ligand Access to the Atypical Hydrophobic Groove of BOK
(A) Alignment of the BCL-2 core of BOK (green) and that of BAX, BCL-xL, and BCL-w completed in PyMOL. The root-mean-square deviation is indicated for the total number of atoms used in the alignment. Top: cartoon representations indicate major deviations in alignments in the region connecting helices α2–α4, which defines the atypical groove of BOK. Bottom: cartoon-and-stick representations of BOK protruding through the surface representation of the aligning partner. Clashes with incoming hydrophobic ligands are predicted throughout the hydrophobic groove of BOK.
(B) The atypical hydrophobic groove of BOK is shown in the apo configuration or interacting with the BID BH3 from the BID SAHB-BAK complex (2m5b.pdb). Left: the electrostatic potential plotted on the surface of BOK. Middle and right: the putative clashes of the BID BH3 ligand at the groove of BOK. The chemical staple of the BID SAHB was excluded (right). The putative hydrophobic pockets are designated as P0–P5.
(C) The alignment of BOK and the BAX-BIM SAHB complex showing a view of the activation site of BAX engaged by BIM SAHB. The predicted structural clashes and electrostatic incompatibilities of BIM SAHB and BOK at this site are illustrated in the surface-cartoon representation, suggesting that their interaction is disfavored. See also Figure S3.
Figure 4.Weak Binding of BID BH3 at the Canonical Hydrophobic Groove of BOK Promotes Membrane Permeabilization at Specific Dosing Combinations
(A) Unstapled and stapled BH3 peptides. Residues highlighted in black are identical between BID and BOK BH3. X, pentenyl-Ala; B, norleucine.
(B) Overlay of 1H-15N TROSY spectra of 15N-labeled G35A PR3CA titration with BID BH3 at 303 K and pH 5.0.
(C) CSP magnitudes in G35A PR3CA induced by 200 μM BID BH3 at 303 K and pH 5.0 (Figure S4B) were plotted over the cartoon putty representation of WT PR3CA. Putty thickness correlates with CSP magnitude.
(D) MOMP assay of purified bak− mitochondria by WT PR4CA-CH in the presence of unstapled and stapled BH3 peptides and the DMSO vehicle control for monitoring cyt c release and protein loading.
(E) Combined average and SE of AUC at 32 min for WT and mutant PR4CA-CH in the presence of unstapled and stapled BH3 peptides and DMSO vehicle control for the normalized LUVP in Figure S4G. Data were corrected for LUVP induced by peptides and vehicle alone (Figure S4F). Peptide concentrations were empirically selected to induce low or no LUVP and MOMP in the absence of BOK.
See also Figure S4.
Figure 5.BID BH3 Engages the Canonical Groove of BOK Similar to that of BAK to Promote Liposome Membrane Permeabilization at Specific Dosing Combinations
(A) Unstapled WT and mutant BID BH3 peptides. Residues highlighted in black are conserved in most BH3-only proteins. Mutations are color coded. B, norleucine.
(B) Cartoon-surface representation of BID BH3 bound to BOK, modeled based on the alignment of BOK NMR structure over the BID BH3-BAK complex (2m5b.pdb). Residues in BID were mutated according to the substitutions in (A). BOK residues that participate in binding have been labeled.
(C) Combined average and SE of AUC at 32 min for WT PR4CA-CH in the presence of unstapled WT and mutant BID BH3 peptides for the normalized LUVP in Figure S5D.
(D) Combined average and SE of AUC at 32 min for WT and mutant BID BH3 peptides alone (Figure S5D).
(E) Overlay of 1H-15N TROSY spectra of 15N-labeled G35A PR3CA titration with WT and mutant BID BH3 at 303 K and pH 6.8.
(F) CSPs plotted against concentration for indicated residues were fitted to a hyperbola to determine the KD for the interaction of G35A PR3CA and the WT BID BH3 peptide. Mutant BID BH3 peptides exhibited weaker binding to BOK compared to the WT.
See also Figure S5.
Figure 6.tBID Does Not Promote BOK-Mediated Cell Death
(A) Schematic of the Tet-On 3G stable expression system of Venus-2A-HA-mouse BOK in bak− bax− MEFs. We typically preincubate cells with Dox for up to 24 hr, which initiates the production of BOK mRNA, and induce cell death with MG132, which inhibits the proteasome, thereby stabilizing BOK protein.
(B) Transient transfection of vectors expressing mCherry (mC) and tBID-mCherry (tBID-mC) was performed according to the scheme in Figure S6A. After recovery in the respective doses of Dox, cell death was induced with MG132 for 18 hr. Western blotting of samples treated with the caspase inhibitor qVD was conducted sequentially with BID, GFP, BOK, and actin antibodies. The blue arrow in the BID blot indicates cross-reactivity by the BID antibody with a band that migrates slightly faster than tBID-mCherry. Weak production of tBID alone also is detected, perhaps being generated through proteolysis of tBID-mCherry. The banding pattern indicates potential BOK ubiquitination.
(C) Cell death induced by WT mBOK in (B) was monitored hourly by IncuCyte imaging of SYTOX Green staining. The 18 hr time point indicates insignificant differences between the mCherry and tBID-mCherry samples at each Dox concentration. Data represent average and SD of triplicate. See also Figure S6.
Figure 7.Intrinsic Instability in Helix a1 Facilitates Membrane Permeabilization to Promote Cell Death
(A) Average and SE of LUVP AUC at 32 min induced by WT and G35A mutant of PR4CA-CH and ΔN-BOK-ΔTM-CH for three independent experiments performed in triplicate.
(B) TSA of WT and G35A mutant of PR4CA-CH and ΔN-BOK-ΔTM-CH. Red dotted lines are at 5°C above the WT Tm. Data represent average Tm and SD of replicate performed in quadruplicate.
(C) Overlay of 1H-15N TROSY spectra of 15N-labeled WT and G35A PR3CA titration with urea indicates a transition at higher urea concentration for the stabilizing mutant G35A compared to WT.
(D) MOMP assay of purified bak− mitochondria by WT and G35A PR4CA-CH for monitoring cyt c release and protein loading.
(E) Western blot of MEFs expressing mBOK probed for BOK, GFP, and actin. Banding pattern indicates potential BOK ubiquitination.
(F) Cell death of WT and G35A mBOK, induced at 24 hr according to IncuCyte imaging of SYTOX Green staining and FACS of PI staining. Data represent average and SD of triplicate.
(G) Transient transfection with empty vector (EV) and tBID-mCherry (tBID-mC) of mBOK-expressing cells was performed according to the scheme in Figure S6A. After recovery in the respective doses of Dox, cell death was induced with MG132 for 18 hr. Cell death induced by WT mBOK was monitored hourly by IncuCyte imaging of SYTOX Green staining. The 18 hr time point indicates insignificant differences between the EV and tBID-mCherry samples at the higher Dox concentration. Transient transfection of tBID-mC was more toxic than that by the EV control, as indicated by significant cell death in the absence of Dox (Dox 0). Black and red arrows show comparable levels of BOK as determined in (H). Data represent average and SD of triplicate.
(H) Western blotting of samples treated with the caspase inhibitor qVD in (G) was conducted sequentially with BID, GFP, BOK, and actin antibodies. Weak production of tBID alone also is detected, perhaps being generated through the proteolysis of tBID-mCherry. Banding pattern indicates potential BOK ubiquitination. Black and red arrows show comparable levels of BOK, which have been integrated and normalized to G35A. Their values are indicated below the arrows.
(I) BOK-mediated MOMP is achieved by inhibition of the ERAD gp78-proteasome system, which stabilizes BOK protein and results in its accumulation. Built-in metastability of BOK is governed in part by (1) conformational exchange in the hydrophobic groove and (2) intrinsic instability conferred by G35 in helix a1 (purple rod), which is critical in driving (3) spontaneous membrane association, MOMP, and cell death initiation. G35A mutation blocks BOK-mediated cell death. Helix a1 dissociation from the rest of the BCL-2 core is shown for emphasis, but it was not demonstrated. The color change of BOK as it interacts with the OMM indicates a different unknown conformation than soluble BOK.
See also Figure S7.
KEY RESOURCES TABLE
| REAGENT or RESOURCE | SOURCE | IDENTIFIER |
|---|---|---|
| Experimental Models: Strains/Cell Lines | ||
| Agilent Technologies | Cat# C404010 | |
| Thermo Fisher Scientific | Cat# C601003 | |
| New England Biolabs | Cat# C2566I | |
| New England Biolabs | Cat# C3013I | |
| Phoenix Ampho Packaging Cells | ATCC | Cat# CRL-3213 |
| Immortalized SV40
| ( | PMID 26949185 |
| Jackson Laboratories | B6.129- | |
| Peptides | ||
| hBID_BH3: EDIIRNIARHLAQVGDSBDRSI (B = Nle) | This paper | N/A |
| hBID_BH3a: EDIIRNAARHLAQVGDSMDRSI | This paper | N/A |
| hBID_BH3b: EDIIRNIARHAAQVGDSMDRSI | This paper | N/A |
| hBID_BH3c: EDIIRNAARHAAQVGDSMDRSI | This paper | N/A |
| hBID_BH3d: EDIIRNIARHLWQVGDSMDRSI | This paper | N/A |
| hBID_BH3e: EDIIRNAARHLWQVGDSMDRSI | This paper | N/A |
| hBID SAHB: EDIIRNIARHLAXVGDXBDRSI (X = pentenyl alanine) | This paper | N/A |
| hBOK BH3: RLAEVCAVLLRLGDELEBIR | This paper | N/A |
| hBOK SAHB: RLAEVSAVLLXLGDXLEBIR | This paper | N/A |
| Recombinant DNA | ||
| pRetroX-TRE3G | Clontech | Cat# 631188 |
| pcDNA3.1 | Invitrogen | Cat# V79020 |
| pEGFP N1 | Clontech | Cat# 6085–1 |
| pNIC28-Bsa4 | ( | Addgene #26103 |
| Human BOK and mutants in pNIC28-Bsa4 | This paper | N/A |
| Mouse BOK and mutants in pRetroX-TRE3G | ( | PMID 26949185; N/A |
| FLAG-human tBID and mutants in pcDNA3.1 | ( | PMID 22036586; N/A |
| Human tBID-mCherry in pEGFP N1 | ( | PMID 22036586 |
| Chemicals | ||
| Fetal Bovine Serum - Premium Select | Atlanta Biologicals | Cat# S11550 |
| DMEM, high glucose, no phosphates | Thermo Fisher Scientific | Cat# 11971025 |
| GIBCO L-glutamine | Thermo Fisher Scientific | Cat# 25030081 CAS# 56-85-9 |
| GIBCO Penicillin-Streptomycin | Thermo Fisher Scientific | Cat# 15140122 CAS# 69-57-8, 57-92-1 |
| GIBCO Sodium Pyruvate | Thermo Fisher Scientific | Cat# 11360070 CAS# 113-24-6 |
| GIBCO MEM Non-Essential Amino Acids Solution | Thermo Fisher Scientific | 11140050 |
| GIBCO 2-Mercaptoethanol | Thermo Fisher Scientific | Cat# 21985023 CAS# 60-24-2 |
| 0.25% Trypsin, 0.1% EDTA in HBSS w/o Calcium, Magnesium and Sodium Bicarbonate | Corning | 25053CI |
| Lipofectamine 3000 | Thermo Fisher Scientific | Cat# L3000015 |
| Zeocine | Thermo Fisher Scientific | Cat# R25001 |
| Blastocidine S HCl powder | Thermo Fisher Scientific | Cat# R21001 |
| Doxycycline | Clontech | Cat# 631311 CAS# 24390-14-5 |
| Z-Leu-Leu-Leu-al (MG132) | Sigma Aldrich | Cat# C2211 |
| CAS# 133407-82-6 | ||
| SYTOX Green | Thermo Fisher Scientific | Cat# S7020 CAS# 163795-75-3 |
| Q-VD-Oph hydrate | APExBIO | Cat# A1901 |
| Propidium Iodide | Invitrogen | Cat# P3566 CAS# 25535-16-4 |
| L-α-phosphatidylcholine (Egg, Chicken) | Avanti Polar Lipids | Cat# 840051C CAS# 97281-44-2 |
| L-α-phosphatidylinositol (Liver, Bovine) (sodium salt) | Avanti Polar Lipids | Cat# 840042C CAS# 383907-33-3 |
| L-α-phosphatidylserine (Brain, Porcine) (sodium salt) | Avanti Polar Lipids | Cat# 840032C CAS# 383907-32-2 |
| Cardiolipin (Heart, Bovine) (sodium salt) | Avanti Polar Lipids | Cat# 840012C CAS# 383907-10-6 |
| 1,2-dioleoyl- | Avanti Polar Lipids | Cat# 790404C CAS# 231615-77-3 |
| 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine | Avanti Polar Lipids | Cat# 850725C CAS# 4004-05-1 |
| ANTS (8-aminonpaphthalene-1,3,6-trisulfonic acid, disodium salt) | Molecular Probes | Cat# 1278701 CAS# 5398-34-5 |
| DPX (p-xylene-bis-pyridiunium bromide) | Molecular Probes | Cat# X1525 CAS# 14208-10-7 |
| 15N Ammonium Chloride | Cambridge Isotope Laboratories | Cat# NLM-467–10 CAS# 12125-02-9 |
| 13C Glucose | Cambridge Isotope Laboratories | Cat# CLM-1396–1 CAS# 50-99-7 |
| Deuterated DTT | Cambridge Isotope Laboratories | Cat# DLM-2622–1 |
| Deuterium Oxide | Sigma Aldrich | Cat# 617385–1 CAS# 7789-20-0 |
| Deuterated DMSO | Sigma Aldrich | Cat# 151874 |
| Ponceau S | G-Biosciences | Cat# 786–576 |
| cOmplete, Mini Protease Inhibitor Cocktail | Roche | Cat# 11836153001 |
| Antibodies | ||
| Anti-cyt | BD Biosciences | Cat# 556433; RRID:AB_396417 |
| Anti-human BID monoclonal antibody | Santa Cruz | Cat# SC-56025; RRID:AB_781628 |
| Anti-human BOK monoclonal antibody | Abcam | Cat# ab186745 |
| Anti-GFP monoclonal antibody | Santa Cruz | Cat# SC-9996; RRID:AB_627695 |
| Anti-actin monoclonal antibody | Millipore Sigma | Cat# MAB1501; RRID:AB_2223041 |
| Critical Commercial Assays | ||
| QuikChange II XL Site-Directed Mutagenesis Kit | Agilent Technologies | Cat# 200522 |
| QIAprep Spin Miniprep Kit | QIAGEN | Cat# 27106 |
| Plasmid Plus Midi Kit | QIAGEN | Cat# 12945 |
| Protein Thermal Shift Starter Kit | Thermo Fisher Scientific | Cat# 4462263 |
| Supersignal West Dura | Thermo Fisher Scientific | Cat# 34075 |
| Deposited Data | ||
| Human BOK structure | This paper | PDB: 6CKV.pdb; BioMagResBank: 304023 |
| Software and Algorithms | ||
| TopSpin v3.2 | Bruker BioSpin | |
| CARA v1.9.1.7 | ( | |
| TALOS+ | ( | |
| UNIO’10 v2.0.1 | ( | |
| CYANA v2.1 | (Guntert, 2004) | |
| MOLMOL v2.1–2.6 | ( | |
| PROCHECK v3.4.3 | ( | |
| ProtSkin | ( | |
| MacPyMOL v1.7.6.3 | Schrodinger, LLC | |
| ImageJ | NIH, USA | |
| IncuCyte v2016A | Essen BioScience | |
| IncuCyte 2011A Rev2 v20111.3.4288 | Essen BioScience | |
| FlowJo Xv10.0.7r2 | FlowJo, LLC | |
| Microsoft Excel | Microsoft | |
| Prism v7.0a | GraphPad Software | |
| Protein Thermal Shift Software v1.3 | Thermo Fisher Scientific | Cat# 4466037 |
| ABI 7900HT Sequence Detection Systems v 2.4.1 | Thermo Fisher Scientific | Cat# 4350490 |
| ClarioSTAR Microplate Reader Software V5.40 Edition 2; Reader Control v5.40; Firmware v1.20; MARS Data Analysis v3.30 | BMG Lab Tech | |
| Other | ||
| Nickel agarose beads (high density) | Gold Biotechnology | Cat# H-320–500 |
| Amicon Ultra 15-mL 3K MWCO centrifugal filter | Millipore Sigma | Cat# UFC900324 |
| Amicon Ultra 15-mL 10K MWCO centrifugal filter | Millipore Sigma | Cat# UFC800324 |
| MonoS 5/50 GL column | GE Healthcare | Cat# 17-5168-01 |
| Superdex200 Increase 10/300 GL column | GE Healthcare | Cat# 28990944 |
| HiPrep 16/60 Sephacryl S-500 HR column | GE Healthcare | Cat# 28935606 |